Product Development Progress - The company announced that its raw material drug, hydrochloride erlotinib, received approval for market application from the National Medical Products Administration on February 3, 2026. This drug is intended for the treatment of non-small cell lung cancer and is expected to enrich the company's product line and enhance market competitiveness [2] Performance and Operating Conditions - On January 20, 2026, the company released its annual performance forecast for 2025, estimating a net profit attributable to shareholders of between 31 million and 39 million yuan, representing a year-on-year decline of 57.40% to 66.14%. The non-recurring net profit is expected to decline by 88.76% to 92.46% year-on-year. The decline in performance is primarily attributed to intensified market competition for ibuprofen raw materials and a decrease in gross profit margin [3] Shareholder Movements - An announcement on November 12, 2025, indicated that three shareholders plan to collectively reduce their holdings in the company by no more than 2.33%. This reduction is scheduled to occur within three months following the announcement, starting 15 trading days after the disclosure. This movement may impact the company's equity structure [4] Financial Situation - Data from January 2026 shows that the company's main funds are in a net inflow state, with a net inflow of 4.9655 million yuan on January 7. This reflects short-term changes in the financial situation and resonates with market sentiment [5]
亨迪药业盐酸埃克替尼获批，2025年业绩预降超五成